(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug Leqembi, which was recently approved under the agency’s accelerated review process.

(Reporting by Bhanvi Satija in Bengaluru; Editing by William Mallard)